Amicus Therapeutics, Inc. Board of Directors

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Dr. Jill Weimer Ph.D.

Dr. Jill Weimer Ph.D.

Chief Science Officer

Mr. Andrew Faughnan

Mr. Andrew Faughnan

Senior Director of Investor Relations

Dr. Jeffrey P. Castelli Ph.D.

Dr. Jeffrey P. Castelli Ph.D.

Chief Development Officer

Ms. Ellen S. Rosenberg J.D.

Ms. Ellen S. Rosenberg J.D.

Chief Legal Officer & Corporate Secretary

Mr. Patrik S. Florencio Esq.

Mr. Patrik S. Florencio Esq.

Global Chief Compliance & Risk Officer

Mr. David M. Clark

Mr. David M. Clark

Chief People Officer

Ms. Samantha Prout

Ms. Samantha Prout

Chief Accounting Officer & Controller

Ms. Diana Moore

Ms. Diana Moore

Head of Global Corporate Communications

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.